Analysts bullish on Boston Scientific's plans for 75 new products by 2022

Boston Scientific CEO Michael Mahoney laid out the long-term strategy for the company late last week, including a plan to launch 75 new cardiac valve, brain stimulation and other products by 2022.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.